Cargando…
Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients
Refractory bone and soft tissue sarcomas are challenging diseases to treat because of their robustness to chemotherapy. Although cancer vaccines have the potential to become an attractive treatment modality, their progress has been hampered by the presence of many subtypes of sarcomas and different...
Autores principales: | Takahashi, Ryuji, Ishibashi, Yukinao, Hiraoka, Koji, Matsueda, Satoko, Kawano, Kouichirou, Kawahara, Akihiko, Kage, Masayoshi, Ohshima, Koichi, Yamanaka, Ryuya, Shichijo, Shigeki, Shirouzu, Kazuo, Itoh, Kyogo, Sasada, Tetsuro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656559/ https://www.ncbi.nlm.nih.gov/pubmed/23829867 http://dx.doi.org/10.1111/cas.12226 |
Ejemplares similares
-
Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients
por: Iwasa, Satoru, et al.
Publicado: (2016) -
Antitumor activity of antibody against cytotoxic T lymphocyte epitope peptide of lymphocyte‐specific protein tyrosine kinase
por: Matsueda, Satoko, et al.
Publicado: (2018) -
Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptides
por: Fukui, Akimasa, et al.
Publicado: (2012) -
Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients
por: Takahashi, Ryuji, et al.
Publicado: (2014) -
Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib
por: Azuma, Koichi, et al.
Publicado: (2014)